GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keros Therapeutics Inc (NAS:KROS) » Definitions » Non Operating Income

KROS (Keros Therapeutics) Non Operating Income : $20.06 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Keros Therapeutics Non Operating Income?

Non Operating Income is income or expense that comes from miscellaneous sources. Keros Therapeutics's Non Operating Income for the three months ended in Sep. 2024 was $5.70 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $20.06 Mil.

Keros Therapeutics Non Operating Income Historical Data

The historical data trend for Keros Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keros Therapeutics Non Operating Income Chart

Keros Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Non Operating Income
Get a 7-Day Free Trial -2.32 -1.33 -0.36 3.03 14.55

Keros Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.84 3.81 5.37 5.18 5.70

Keros Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics Non Operating Income Related Terms

Thank you for viewing the detailed overview of Keros Therapeutics's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Keros Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keros Therapeutics Inc (NAS:KROS) » Definitions » Non Operating Income
Comparable Companies
PLRX REPL PTGX APGE TNGX VTYX SRRK INVA ARVN NWBO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Website
https://www.kerostx.com
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Executives
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Keith Regnante officer: Chief Financial Officer 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Alpna Seth director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Jennifer Lachey officer: Chief Scientific Officer C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Christopher Rovaldi officer: Chief Operating Officer C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139
Julius Knowles director C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Simon Peter Cooper officer: Chief Medical Officer C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421
Claudia Ordonez officer: Chief Medical Officer C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Pontifax Management 4 G.p. (2015) Ltd. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum director, 10 percent owner C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Tomer Kariv director, 10 percent owner C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Jasbir Seehra director, officer: Chief Executive Officer C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Alon Lazarus director, 10 percent owner C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421